{{Rsnum
|rsid=3761422
|Gene=ADORA2A
|Chromosome=22
|position=24430704
|Orientation=plus
|GMAF=0.3802
|Gene_s=ADORA2A,C22orf45
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 37.5 | 49.1 | 13.4
| HCB | 37.5 | 49.3 | 13.2
| JPT | 43.4 | 43.4 | 13.3
| YRI | 38.8 | 47.6 | 13.6
| ASW | 35.1 | 45.6 | 19.3
| CHB | 37.5 | 49.3 | 13.2
| CHD | 43.1 | 36.7 | 20.2
| GIH | 35.6 | 46.5 | 17.8
| LWK | 47.3 | 48.2 | 4.5
| MEX | 44.8 | 46.6 | 8.6
| MKK | 30.2 | 56.4 | 13.4
| TSI | 35.3 | 48.0 | 16.7
| HapMapRevision=28
}}{{PMID Auto
|PMID=20334879
|Title=Adenosine A(2A) receptor gene: Evidence for association of risk variants with panic disorder and anxious personality
}}

{{PharmGKB
|RSID=rs3761422
|Name_s=ADORA2A: g.4217241T>C
|Gene_s=ADORA2A
|Feature=
|Evidence=PubMed ID:18539621
|Annotation=Risk or phenotype-associated allele: rs3761422 T allele. Phenotype: Carriers of 1 or 2 copies of the T allele for rs3761422 showed increased risk of any (OR = 2.11, CI = 1.04-4.39, p = 0.02) or gastrointestinal-specific (OR = 1.91, CI = 0.69-5.77, p = 0.17) adverse events. Study size: 309 RA patients, including 147 good MTX responders, 101 MTX inefficacy failures, and 61 adverse event (AE) MTX failures (e.g. gastrointestinal (n = 24), abnormal liver function tests (n = 20), haematological (n = 7), skin rashes (n = 6), and other (n = 17). Study population/ethnicity: Rheumatoid arthritis (RA) patients aged over 18 yrs, of White Caucasian ethnic origin, classified as having RA according to ARA criteria that were retrospectively recruited from University Hospital of North Staffordshire (UHNS) and Central Manchester and Manchester Children&apos;s University Hospitals Trust (CMMC) in England. Significance metric(s): OR = 2.11 and 1.91, p = 0.02-0.17. Type of association: GN; PD; TOX; ADR.
|Drugs=methotrexate
|Drug Classes=
|Diseases=Arthritis, Rheumatoid; Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165110742
}}

{{PMID Auto
|PMID=18305461
|Title=Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety.
|OA=1
}}

{{PMID Auto
|PMID=19565319
|Title=Adenosine A(2A) receptor gene (ADORA2A) variants may increase autistic symptoms and anxiety in autism spectrum disorder.
}}

{{PMID Auto
|PMID=20386734
|Title=Further evidence supporting a role for gs signal transduction in severe malaria pathogenesis.
|OA=1
}}

{{PMID Auto
|PMID=20520601
|Title=Association of the anxiogenic and alerting effects of caffeine with ADORA2A and ADORA1 polymorphisms and habitual level of caffeine consumption.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs3761422
|overall_frequency_n=85
|overall_frequency_d=128
|overall_frequency=0.664062
|n_genomes=49
|n_genomes_annotated=0
|n_haplomes=73
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23332182
|Title=A study of the possible association between adenosine A2A receptor gene polymorphisms and attention-deficit hyperactivity disorder traits.
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}